Levrett Plc (LON:LVRT), a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, today made the following comment regarding the Timmerman Report which was published earlier this month:
“Bull market or Bubble… Luke Timmerman of the excellent Timmermanreport.com hosts a highly informative panel discussion with some of the leading players in the Biotech industry at the recent Milken Institute conference discussing the current (very positive) outlook for the biotech sector together with some of the challenges it faces such as the drug pricing controversy of recent months, the high cost of new drug development, and how they can be addressed to ensure society has access to innovative therapies and drugs and investors continue to be incentivised to invest to help scientists deliver those innovation – topics close to all our hearts.”
Levrett Plc CEO Pascal Hughes is a financier, investor and entrepreneur. He previously worked in Investment Banking in the City of London for close to 20 years most recently as a Managing Director in Fixed Income, Currencies and Commodities at UBS bank. Prior to that he was a Managing Director in Global Banking and Markets at HSBC. He left UBS to become an active private investor and advisor to start-up companies in a variety of different business areas from financial technologies to oil field services. During this period he has been involved in developing businesses and advising on acquisition and turn round strategy. Pascal has a B.A (Hons) in Accounting and Finance from Dublin City University, and an MSc. in Financial Economics from Queens University Belfast.
